



July 20, 2018

BSE Limited
Floor 25, P. J. Towers
Dalal Street,
Mumbai - 400 001

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra (E)
Mumbai - 400 051

Dear Sirs,

We enclose a communication pertaining to I-131 MIBG OPTIMUM Trials.

This is for your kind information and record.

Thanking You,

Yours faithfully,
For Jubilant Life Sciences Limited

Rajiv Shah
Company Secretary

Encl.: as above

A Jubilant Bhartia Company

OUR VALUES



Jubilant Life Sciences Limited

1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubl.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223,
UP, India
CIN : L24116UP1978PLC004624



Jubilant Life Sciences Ltd.

1A, Sector 16A, Noida – 201301, India

Tel.: +91 120 4361000

www.jubl.com

Jubilant initiates I-131 MIBG OPTIMUM Trials

Noida (UP), India, Friday, July 20, 2018

Jubilant Life Sciences Ltd, an integrated global Pharmaceuticals and Life Sciences Company, has announced that its wholly own subsidiary Jubilant Pharma Limited, through one of its units Jubilant DraxImage Inc. Montreal, Canada, has initiated OPTIMUM trial which is a Pivotal Phase II Clinical Trial designed to prove the safety and effectiveness of I-131 MIBG for the treatment of neuroblastoma. The study will include both male and female patients over the age of one year who show a return or persistence of this disease following initial therapy. Children enrolled in the OPTIMUM trial could receive up to two dose cycles of I-131 MIBG over a twenty-six week period.

The information collected from this study will be submitted to the United States Food and Drug Administration (FDA) under the Orphan Drug Designation program and is eligible for accelerated approval if the clinical trials are successful. Jubilant's MIBG has already been used for over a decade in USFDA approved expanded access trials and two Pediatric Oncology academic consortiums – NANT (New Approaches to Neuroblastoma Therapy) and COG (Children's Oncology Group).

Commenting on the occasion, **Mr. Shyam S. Bhartia, Chairman and Mr. Hari S. Bhartia, Co-Chairman and Managing Director, Jubilant Life Sciences Limited** said: "We are extremely pleased that JDI can offer these critical therapeutic options to children who suffer from this rare cancer. The initiation of this pivotal trial is a crucial step for Jubilant's MIBG NDA filing and is a testimony to our Specialty R&D capability to develop complex products addressing advanced medical needs."

About Jubilant Life Sciences Limited

Jubilant Life Sciences Limited is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions. The Pharmaceuticals segment, through its wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile and Non-sterile products through 6 USFDA approved manufacturing facilities in India, USA and Canada and a network of over 50 radio-pharmacies in the US. The Life Science Ingredients segment, is engaged in Specialty Intermediates, Nutritional Products and Life Science Chemicals through 5 manufacturing facilities in India. The Drug Discovery Solutions segment, provides proprietary in-house innovation & collaborative research and partnership for out-licensing through 3 world class research centres in India and USA. Jubilant Life Sciences Limited has a team of around 7,600 multicultural people across the globe and is committed to deliver value to its customers across over 100 countries. The Company is well recognized as a 'Partner of Choice' by leading pharmaceuticals and life sciences companies globally. For more info: www.jubl.com.



For more information, please contact:

For Investors

Ravi Agrawal / Anupam Jain
Jubilant Life Sciences Limited
Ph: +91-120 436 1002 / 1021
E-mail: ravi.agrawal@jubl.com
anupam.jain@jubl.com

Siddharth Rangnekar / Karl Kolah
Citigate Dewe Rogerson
Ph: +91 22 6645 1209 / 1220
E-mail: siddharth@cdr-india.com
karl@cdr-india.com

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.